Minerva Neurosciences to Present at Jefferies Virtual London Healthcare Conference
09 nov. 2020 08h30 HE
|
Minerva Neurosciences, Inc
WALTHAM, Mass., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat...
Minerva Neurosciences Reports Third Quarter 2020 Financial Results And Business Updates
02 nov. 2020 07h30 HE
|
Minerva Neurosciences, Inc
WALTHAM, Mass., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
Minerva Neurosciences to Report Third Quarter 2020 Financial Results and Business Updates on November 2, 2020
26 oct. 2020 08h30 HE
|
Minerva Neurosciences, Inc
WALTHAM, Mass., Oct. 26, 2020 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
Minerva Neurosciences to Present at H.C. Wainwright 22nd Annual Global Investment Conference
09 sept. 2020 08h30 HE
|
Minerva Neurosciences, Inc
WALTHAM, Mass., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat...
Minerva Neurosciences to Present at Citi's 15th Annual BioPharma Virtual Conference
02 sept. 2020 08h30 HE
|
Minerva Neurosciences, Inc
WALTHAM, Mass., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat...
Minerva Neurosciences to Present at JMP Securities CNS Forum
13 août 2020 08h00 HE
|
Minerva Neurosciences, Inc
WALTHAM, Mass., Aug. 13, 2020 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat...
Minerva Neurosciences Reports Second Quarter 2020 Financial Results and Business Updates
03 août 2020 07h30 HE
|
Minerva Neurosciences, Inc
WALTHAM, Mass., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
Minerva Neurosciences to Report Second Quarter 2020 Financial Results and Business Updates on August 3, 2020
27 juil. 2020 08h00 HE
|
Minerva Neurosciences, Inc
WALTHAM, Mass., July 27, 2020 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
Minerva Neurosciences Exercises Right to Opt Out of Agreement With Janssen for Seltorexant (MIN-202)
01 juil. 2020 08h00 HE
|
Minerva Neurosciences, Inc
Preserves royalties payable to Minerva on worldwide sales of seltorexant Eliminates all financial obligations with respect to the clinical development and commercialization of seltorexantCorporate...
REVISED WEBCAST & CALL INFORMATION: Minerva Neurosciences to Hold Webcast and Call With Key Opinion Leaders to Present Additional Analyses From Phase 3 Trial of Roluperidone (MIN-101) for Treatment of Negative Symptoms in Schizophrenia
01 juin 2020 08h00 HE
|
Minerva Neurosciences, Inc
WALTHAM, Mass., June 01, 2020 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...